|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Fatigue gradually decreased after a peak at the 1st CTx cycle in Exp 2, whereas Exp 1 experienced increasing fatigue until the 3rd CTx cycle.
|
31129760 |
2020 |
|
Neuromuscular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The XPO1 protein is an important regulator of key inflammatory and neurological factors that drive inflammation and neurotoxicity in various neurological and neuromuscular diseases.
|
31628052 |
2020 |
|
Sleep disturbances
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
A gradual decrease in sleep disturbance was observed in Exp 2 after the 2nd CTx cycle, whereas Exp 1 experienced a steady increase in the symptom.
|
31129760 |
2020 |
|
Malignant Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selinexor, an orally bioavailable, reversible inhibitor of the nuclear export protein, exportin 1, is in clinical trials for a range of cancers, including HGG.
|
31594826 |
2020 |
|
Dyssomnias
|
0.010 |
Biomarker
|
disease |
BEFREE |
A gradual decrease in sleep disturbance was observed in Exp 2 after the 2nd CTx cycle, whereas Exp 1 experienced a steady increase in the symptom.
|
31129760 |
2020 |
|
Sleep Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
A gradual decrease in sleep disturbance was observed in Exp 2 after the 2nd CTx cycle, whereas Exp 1 experienced a steady increase in the symptom.
|
31129760 |
2020 |
|
High grade glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selinexor, an orally bioavailable, reversible inhibitor of the nuclear export protein, exportin 1, is in clinical trials for a range of cancers, including HGG.
|
31594826 |
2020 |
|
Cooley's anemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Here we demonstrate that in normal erythroid progenitors, HSP70 localization is regulated by the exportin-1 (XPO1), and that treatment of β-thalassemic erythroblasts with an XPO1 inhibitor increased the amount of nuclear HSP70, rescued GATA-1 expression and improved terminal differentiation, thus representing a new therapeutic option to ameliorate ineffective erythropoiesis of β-TM.
|
31753924 |
2019 |
|
beta Thalassemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
XPO1 regulates erythroid differentiation and is a new target for the treatment of β-thalassemia.
|
31753924 |
2019 |
|
Mucinous Adenocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
After neoadjuvant CRT, overall downstaging occurred in 44.4% of MAC and 72.4% of non-MAC (p=0.001), and positive CRM (≤1 mm) was observed more frequently in MAC (p<0.001).
|
30590006 |
2019 |
|
Infection by Cryptococcus neoformans
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these results demonstrate that Cdc50 and Crm1 regulation of the calcineurin pathway and cytoplasmic calcium homeostasis may underlie caspofungin resistance in <i>C. neoformans</i><b>IMPORTANCE</b><i>Cryptococcus neoformans</i> is the leading cause of fungal meningitis, accounting for ∼15% of HIV/AIDS-related deaths, but treatment options for cryptococcosis are limited.
|
31822582 |
2019 |
|
Acute Promyelocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
XPO1 inhibition induced cell cycle arrest through p53 activation, but the mechanisms of p53 activation differed among the different types of cancer cells. p53 activation depended on the formation of promyelocytic leukemia (PML) nuclear bodies in gastric cancer and liver cancer cells.
|
31088931 |
2019 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.010 |
Biomarker
|
disease |
BEFREE |
XPO1 inhibition induces cell arrest through a novel PML- and p62-dependent mechanism of p53 activation in some types of cancer cells.<b>IMPORTANCE</b> Using a model of oncogenic virus KSHV-driven cellular transformation of primary cells, we have performed a genome-wide CRISPR-Cas9 screening to identify vulnerable genes of cancer cells.
|
31088931 |
2019 |
|
Lymphoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Effective and durable disease control was, however, observed by selective inhibition of nuclear export protein exportin-1 (XPO1) using a compound currently in clinical development for relapsed/refractory malignancies, including CLL and lymphoma.
|
31296529 |
2019 |
|
Atrial Premature Complexes
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>XPO1</i> expression refines the prognostication in PAC and higher expression exists in secondary versus primary tumors, which supports the development of <i>XPO1</i> inhibitors in this so-lethal disease.
|
31052304 |
2019 |
|
Progeria
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings provide novel insights into HGPS pathophysiology, identifying CRM1 as potential therapeutic target in HGPS.
|
31305018 |
2019 |
|
Retroviridae Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Our data strongly suggest that ANP32A and ANP32B play an important role in the Rev-CRM1 pathway, which is essential for HIV-1 replication, and our findings provide a candidate therapeutic target for host defense against retroviral infection.
|
31444273 |
2019 |
|
Kaposi Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We performed a clustered regularly interspaced short palindromic repeat (CRISPR)-associated (Cas) screening in a unique model of matched primary and oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV)-transformed cells and identified genes that were growth promoting and growth suppressive for both types of cells, among which exportin XPO1 was demonstrated to be critical for the survival of transformed cells.
|
31088931 |
2019 |
|
Epstein-Barr Virus Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Modules analysis revealed that cyclin-dependent kinase 1 and exportin 1 were involved in the pathway of Epstein-Barr virus infection.
|
31289570 |
2019 |
|
Premature aging syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Enhanced nuclear protein export in premature aging and rescue of the progeria phenotype by modulation of CRM1 activity.
|
31305018 |
2019 |
|
hiv-infection/aids
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these results demonstrate that Cdc50 and Crm1 regulation of the calcineurin pathway and cytoplasmic calcium homeostasis may underlie caspofungin resistance in <i>C. neoformans</i><b>IMPORTANCE</b><i>Cryptococcus neoformans</i> is the leading cause of fungal meningitis, accounting for ∼15% of HIV/AIDS-related deaths, but treatment options for cryptococcosis are limited.
|
31822582 |
2019 |
|
Drug-Induced Liver Disease
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Based on this 1:2 matched case-control study, the AA genotype of rs4430924 in XPO1 may be associated with higher risk of anti-TB drug-induced hepatotoxicity in Chinese anti-TB treatment patients.
|
30817003 |
2019 |
|
Adult Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effective and durable disease control was, however, observed by selective inhibition of nuclear export protein exportin-1 (XPO1) using a compound currently in clinical development for relapsed/refractory malignancies, including CLL and lymphoma.
|
31296529 |
2019 |
|
Childhood Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Effective and durable disease control was, however, observed by selective inhibition of nuclear export protein exportin-1 (XPO1) using a compound currently in clinical development for relapsed/refractory malignancies, including CLL and lymphoma.
|
31296529 |
2019 |
|
Promyelocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
XPO1 inhibition induced cell cycle arrest through p53 activation, but the mechanisms of p53 activation differed among the different types of cancer cells. p53 activation depended on the formation of promyelocytic leukemia (PML) nuclear bodies in gastric cancer and liver cancer cells.
|
31088931 |
2019 |